Combination Therapy of Personalized mRNA-0217 Vaccines and Pembrolizumab in Patients With Advanced Solid Tumors
Clinical trial NCT05916248 · RECRUITING
Trial details
- NCT number
- NCT05916248
- Sponsor
- Ruijin Hospital
- Status
- RECRUITING
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-12-20
- Primary completion
- 2026-06-30
- Enrollment
- 34
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.